Merck KGaA To Assign Chimeric Antigen Receptor T-cell Rights To Intrexon

An image of a stock chart Credit: Shutterstock photo

(RTTNews.com) - Intrexon Corp.(XON) and its wholly-owned subsidiary Precigen said that Intrexon assumed agreement with Merck KGaA, Darmstadt, Germany, through its wholly-owned subsidiary Ares Trading, for the development of Chimeric Antigen Receptor T-cell (CAR-T) therapies, which are genetically engineered t-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells.

Upon closing, the agreement will enable Precigen's complete autonomy of its CAR-T program and allow Merck KGaA, Darmstadt, Germany, to maintain an investment in the future potential of next generation CAR-T development.

As per the terms of the agreement, Merck KGaA, Darmstadt, Germany, will assign its exclusive CAR-T development rights to Intrexon, allowing Precigen to continue autonomous development of its proprietary CAR-T technology platform. Merck KGaA, Darmstadt, Germany will receive $150 million in Intrexon stock in exchange for assigning its CAR-T rights.

In addition to receiving $150 million of Intrexon common stock, this agreement also includes a further $25 million investment in Intrexon. In return, Merck KGaA, Darmstadt, Germany, will receive a $25 million convertible note, providing the option to receive either Precigen or Intrexon stock.

Read the original article on RTTNews (http://www.rttnews.com/2964578/merck-kgaa-to-assign-chimeric-antigen-receptor-t-cell-rights-to-intrexon.aspx)

For comments and feedback: contact editorial@rttnews.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.